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Abstract: Monoclonal antibodies (mAbs) targeting the hepatitis C virus 
(HCV) envelope have been raised mainly against envelope protein 2 (E2), 
while the antigenic epitopes of envelope protein 1 (E1) are not fully 
identified. Here we describe the detailed characterization of a human 
mAb, designated A6, generated from an HCV genotype 1b infected patient. 
ELISA results showed reactivity of mAb A6 to full-length HCV E1E2 of 
genotypes 1a, 1b and 2a. Epitope mapping identified a region spanning 
amino acids 230-239 within the N-terminal region of E1 as critical for 
binding. Antibody binding to this epitope was not conformation dependent. 
Neutralization assays showed that mAb A6 lacks neutralizing capacity and 
does not interfere with the activity of known neutralizing antibodies. In 
summary, mAb A6 is an important tool to study the structure and function 
of E1 within the viral envelope, a crucial step in the development of an 
effective prophylactic HCV vaccine. 
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Abstract 43 
Monoclonal antibodies (mAbs) targeting the hepatitis C virus (HCV) envelope have been raised mainly 44 
against envelope protein 2 (E2), while the antigenic epitopes of envelope protein 1 (E1) are not fully 45 
identified. Here we describe the detailed characterization of a human mAb, designated A6, generated 46 
from an HCV genotype 1b infected patient. ELISA results showed reactivity of mAb A6 to full-length 47 
HCV E1E2 of genotypes 1a, 1b and 2a. Epitope mapping identified a region spanning amino acids 230-48 
239 within the N-terminal region of E1 as critical for binding. Antibody binding to this epitope was not 49 
conformation dependent. Neutralization assays showed that mAb A6 lacks neutralizing capacity and does 50 
not interfere with the activity of known neutralizing antibodies. In summary, mAb A6 is an important tool 51 
to study the structure and function of E1 within the viral envelope, a crucial step in the development of an 52 
effective prophylactic HCV vaccine. 53 
 54 
Keywords: hepatitis C virus, envelope protein, antibody, entry, vaccine. 55 
 56 
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1. Introduction 58 
Hepatitis C virus (HCV) is a member of the Hepacivirus genus within the Flaviviridae family. Based 59 
on the 9.6kb-long RNA genome sequence, HCV is classified into 7 genotypes (1-7) and multiple subtypes 60 
(a, b, c, etc.) (Bukh, 2016). More than 170 million people worldwide are estimated to be infected with 61 
HCV (Petruzziello et al., 2016). More than 70% of individuals with acute HCV infection will become 62 
chronically infected, which after several decades may lead to liver cirrhosis and hepatocellular carcinoma. 63 
Despite the remarkable improvement of HCV treatment regimens using direct-acting antivirals (DAAs), 64 
mutations occur that bring about resistance and negatively impact treatment outcome (Li and De Clercq, 65 
2017; Pawlotsky, 2016). The risk of acquiring HCV infection is high among injection drug users due to 66 
the high prevalence of HCV in this population. The high mutation rate of HCV, leading to continuous 67 
release of closely related viral variants that escape the host’s adaptive immune response, represents a 68 
major hurdle for the development of a vaccine. Identification of conserved epitopes that induce protective 69 
immunity would strongly promote vaccine design. 70 
Inside the host cell, viral RNA is translated into a single polyprotein precursor that is cleaved into 71 
structural (core, envelope E1 and E2) and non-structural (P7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) 72 
proteins (Bartenschlager et al., 2011). Structural proteins are responsible for the formation of the HCV 73 
virus particle, while the non-structural proteins are essential for viral replication, translation and assembly. 74 
Our insight in the HCV life cycle was hampered for a long time but the development of the HCV 75 
pseudoparticle (HCVpp) and HCV cell culture (HCVcc) systems paved the way for a more 76 
comprehensive exploration of virus infectivity (Hsu et al., 2003; Wakita et al., 2005). Both systems are 77 
now widely used for studying HCV entry and screening for viral inhibitors (Catanese and Dorner, 2015). 78 
The envelope proteins E1 and E2 are highly glycosylated membrane-associated proteins consisting of an 79 
N-terminal ectodomain and a C-terminal transmembrane domain. The E1 protein is 192 amino acids (AA) 80 
long (from AA 192 to 383) while the E2 glycoprotein is 363 residues (AA 384 to 746) in length according 81 
to the reference strain H77 (accession no. AF011751). E2 functions as mediator for viral entry through 82 
interaction with host attachment factors and receptors (Dubuisson and Cosset, 2014). It is also the main 83 
target for the host’s adaptive immune system. Recently the E1 protein was also shown to be involved in 84 
viral entry and virion assembly (Haddad et al., 2017). 85 
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The essential role of cell-mediated immunity in HCV clearance has been extensively reported 86 
(Abdelwahab, 2016). The early generation of neutralizing antibodies has been associated with resistance 87 
to infection in individuals at high-risk of exposure, spontaneous clearance during acute infection and 88 
sustained virologic response after therapy (Ndongo et al., 2010; Osburn et al., 2014; Swann et al., 2016). 89 
Although the envelope of HCV contains multiple immunogenic epitopes, the majority of monoclonal 90 
antibodies (mAbs) isolated from infected patients or vaccinated animals have been identified as E2-91 
specific (Tabll et al., 2015). The biological activity of these antibodies is diverse and varies from 92 
neutralizing to non-neutralizing or even interfering (Wang et al., 2011a). Polyclonal antibodies from 93 
HCV-infected patients were able to protect animal models like humanized mice and chimpanzees from 94 
HCV challenge (Bukh et al., 2015; Meuleman et al., 2011; Vanwolleghem et al., 2008). We and others 95 
previously reported that neutralizing antibodies targeting the E2 protein could protect from HCV infection 96 
in vitro and in vivo (Desombere et al., 2016; Keck et al., 2016; Mesalam et al., 2016). In addition, 97 
administration of mAb MBL-HCV1, targeting E2, delayed viral rebound following liver transplantation, 98 
while complete protection was reported when combined with the polymerase inhibitor sofosbuvir (Chung 99 
et al., 2013; Smith et al., 2017). These observations point towards the importance of humoral immunity 100 
and neutralizing antibodies in HCV clearance. 101 
Despite the availability of multiple in vitro systems as well as experimental animal models, little is 102 
still known about the structure and actual function of the E1 glycoprotein (Douam et al., 2014; Haddad et 103 
al., 2017; Lavillette et al., 2007; Wahid et al., 2013). Evidence for the immunogenicity and the induction 104 
of neutralizing antibodies by E1 has been reported. However, only few mAbs have been raised against 105 
this protein compared to the numerous anti-E2 mAbs described in the literature. This may be related to 106 
the difficulty to express the E1 protein as a correctly folded monomer (Op De Beeck et al., 2001). 107 
Polyclonal antibodies from mice vaccinated with E1-HCVpp or recombinant E1 protein were able to 108 
neutralize HCVcc (Dreux et al., 2006; Pietschmann et al., 2006). Also, synthetic peptides covering the C 109 
terminal region of E1 were able to react with 32% of sera from infected patients in one study (Siemoneit 110 
et al., 1995) while 92% reactivity was reported in another study (Ray et al., 1994). In addition, immune 111 
sera of rabbits vaccinated with a synthetic peptide encompassing AA 315-323 prevented the binding and 112 
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entry of HCV particles into HepG2 cells (El-Awady et al., 2006). However, this finding has not been 113 
confirmed using the HCVpp or HCVcc systems. 114 
Two main regions have been identified as reactive domains for anti-E1 antibodies. The first region is 115 
the N- terminal region identified by the human mAb H-111 (AA 192-202) (Keck et al., 2004b) and the 116 
murine mAb A4 (AA 197-207) (Dubuisson et al., 1994). While these antibodies recognize E1 presented 117 
on the viral envelope, mAb H-111 is only weakly neutralizing while no neutralization has been reported 118 
for mAb A4. The second region encompasses AA 313-327, which is located at the C terminus and is 119 
identified mainly by mAbs IGH505 and IGH526 (Kong et al., 2015; Meunier et al., 2008). We isolated a 120 
monoclonal antibody, designated A6, from a HCV genotype 1b infected patient. Epitope mapping 121 
identified AA 230-239 within the N-terminal region of E1 as the critical site for binding. This mAb 122 
showed affinity towards a panel of HCV envelope proteins of genotypes 1a, 1b and 2a, but lacked any 123 
neutralizing or interfering activity.  124 
125 
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2. Materials and Methods 126 
2.1. Human sera, cell lines and antibodies 127 
Blood samples were collected from HCV infected patients who were followed at the Ghent 128 
University Hospital. The study was approved by the local ethical committee and all patients involved 129 
gave informed consent. Human embryonic kidney cells (293T) and human hepatoma cell lines (Huh-130 
7.5RFP-NLS-IPS and Hep3B) were grown in Dulbecco’s Modified Eagle’s Medium supplemented with 131 
10% fetal calf serum, 1% non-essential amino acids, 1% L-glutamine and antibiotics. The human anti-E1 132 
mAb IGH526, the murine anti-E1 mAb A4, the murine anti-E2 mAb AP33 and the human anti-E2 mAbs 133 
MRCT10, 1:7, HC84.26, CBH-7 and HC-1AM were previously described (Allander et al., 2000; 134 
Dubuisson et al., 1994; Keck et al., 2004a; Keck et al., 2012; Kong et al., 2015; Owsianka et al., 2001; 135 
Pantua et al., 2013; Wang et al., 2011b).  136 
 137 
2.2. Amplification and expression of HCV envelope  138 
RNA was extracted from the plasma of infected patients using ZR Viral RNA kit (Zymo Research) 139 
followed by cDNA synthesis using superscript III reverse transcriptase (Invitrogen) and random primers. 140 
The full-length E1E2 sequence was amplified by nested PCR. The first PCR was performed using 141 
LongAmp DNA polymerase (NEB) and the following primers: (F) 5`-CGT AGG TCG CGT AAC TTG 142 
GGT AA-3′ and (R) 5`-GTG CGC CTC GGC CCT GGT GAT AAA-3`. The second-round PCR was 143 
performed using Pfu DNA polymerase (Promega) and primers: (F) 5'-TAT AGA TAT CAT GGG GTA 144 
CAT TCC GCT CGT C-3' and (R) 5'-ATA TGA TAT CTT ACT CAG CCT GAG CTA TCA G-3'. PCR 145 
products were analyzed using 1% agarose gel electrophoresis and the bands corresponding to E1E2 were 146 
eluted and cloned into the pCDNA3.1/Hygro expression vector (Invitrogen). The inserts were sequenced 147 
(Center for Medical Genetics, Ghent University, Belgium), multiple aligned and analyzed using BioEdit 148 
version 7.2.0, Clone manager 9 professional and CLC main workbench version 7.6.4 (QIAGEN). HCV 149 
E1E2 sequences covering all 7 genotypes (1a, 1b, 2a, 2b, 3a, 4a, 5a, 6a and 7a) were retrieved from the 150 
European HCV database (https://euhcvdb.ibcp.fr/euHCVdb/) and the NCBI 151 
(https://www.ncbi.nlm.nih.gov/nucleotide/) and used for alignment with Belgian isolates. Based on amino 152 
acid sequences of the whole E1E2, neighbor joining phylogenetic tree was constructed using 1000 153 
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replicates bootstrapping analysis of CLC main workbench version 7.6.4. For expression of E1E2 in 154 
mammalian cells, constructs encoding the E1E2 region of genotypes 1-6 were used for transfection of 155 
293T cells using ProFection mammalian transfection kit (Promega). After 48 hours, lysis buffer (Promega) 156 
and protease inhibitors (Roche) were added and the cell lysate was centrifuged at 13,000 rpm and 4°C. 157 
The supernatant was collected and stored at –80°C until use. Constructs containing the following viral 158 
strains were used: H77, UKN1A20.8, UKN1A14.38, J4, UKN1B5.23, UKN1B12.16, P5VD, P5VE, 159 
P5VF, JFH1, UKN2A1.2, UKN2B2.8, S52, UKN4.11.1, UKN5.14.4 and UKN6.5.8 in addition to 28 160 
Belgian isolates (Desombere et al., 2016; Fafi-Kremer et al., 2010; Lavillette et al., 2005; Owsianka et al., 161 
2005). 162 
 163 
2.3. Generation of anti-HCV mAb 164 
The hybridoma cells were generated from the peripheral blood mononuclear cells (PBMCs) of a 165 
genotype 1b HCV infected patient as described previously (Depraetere et al., 2001). Clones that secreted 166 
E1-specific antibodies were identified using a prototype version of the INNO-LIA® HCV antibody test 167 
(Innogenetics, Belgium). After subcloning, one E1-specific hybridoma cell line was retained and 168 
designated A6. Cells were propagated in a specific antibody production bioreactor (Integra) and the 169 
culture supernatant was harvested. mAb A6 was purified using a protein G column (GE Healthcare Life 170 
Sciences), concentrated using Amicon centrifugal filters with 50 kDa cut-off (Merck Millipore) and the 171 
concentration was estimated using a commercial human IgG ELISA quantification kit according to 172 
manufacturer instructions (Bethyl Laboratories).  173 
 174 
2.4. GNA binding, competition and denaturation ELISA 175 
The binding affinity of mAb A6 to cell lysate containing recombinant HCV envelope glycoproteins 176 
was tested using GNA binding ELISA as previously described with some modifications (Owsianka et al., 177 
2005). Briefly, ELISA plates were coated with Galanthus nivalis lectin (GNA) and incubated overnight at 178 
4°C. The next day, plates were washed (PBS-0.05% Tween 20) and blocked (PBS-5% BSA) for 1 hour at 179 
room temperature (RT), after which cell lysate was added and incubated for 2 hours. After washing, 180 
diluted mAbs (PBS-5% BSA, 20% goat serum, 0.05% Tween 20) were added and plates were incubated 181 
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1.5 hours followed by addition of HRP-conjugated goat anti-host IgG (anti-human for A6 and 1:7 or anti-182 
mouse for A4). In case of peptide competition assay, serial dilutions of peptides were mixed with a fixed 183 
concentration of mAb A6 (20 µg/mL) before addition to wells. TMB substrate was added and the optical 184 
density (OD) was read at 450nm. Competition ELISA was performed using a previously described 185 
protocol with some modifications (Potter et al., 2012). Briefly, the GNA-coated plates were loaded with 186 
E1E2 cell lysate diluted in blocking buffer (2.5% BSA, 2.5% goat serum, 0.1% Tween 20) and incubated 187 
for 2 hours. Plates were washed and serial dilutions of competing mAbs (A6 or MRCT10) were added. 188 
After 1 hour, biotinylated AP33 was added at a concentration corresponding to 60-75% of the maximum 189 
OD value and incubated for 1 hour. Plates were washed and HRP-conjugated streptavidin was added for 190 
30 min. In denaturation ELISA, cell lysates were incubated with 0.5% sodium dodecyl sulfate (SDS) and 191 
5 mM dithiothreitol (DTT) for 15 min at 56°C (Keck et al., 2012).  192 
 193 
2.5. Protein electrophoresis and Immunoblotting 194 
To test the specificity of mAb A6 binding, lysate of 293T cells expressing H77 E1E2 was used in 195 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Samples were mixed with 4X 196 
Bolt LDS sample and reducing buffers (Life Technologies) followed by heating at 70°C for 10 minutes. 197 
In case of deglycosylation, the cell lysate was first treated with PNGase F or Endo H (NEB) according to 198 
manufacturer instructions. Samples were then resolved on 12% acrylamide gel followed by transfer to 199 
nitrocellulose membrane and blocked for one hour at RT using 5% non-fat milk in TBS-T (TBS-0.05% 200 
Tween 20). After washing (TBS-T), mAb A6 was added (1 µg/mL) followed by 2 hours incubation at RT. 201 
HRP-conjugated goat anti-human IgG (Fc-specific) was added followed by one hour incubation. Bands 202 
were visualized using Pierce ECL Plus western blotting substrate (Thermo Scientific) and imaged on an 203 
ImageQuant LAS 4000 (GE Healthcare Life Sciences). Molecular weights were estimated based on the 204 
MagicMark XP western protein standard (Invitrogen). 205 
 206 
2.6. Epitope mapping  207 
To identify the region critical for mAb binding, a 15-mer, 14-AA overlapping peptide microarray 208 
(PEPperCHIP) was used according to the manufacturer’s instructions (PEPperPRINT GmbH, Germany). 209 
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The peptides printed on the chip were designed to cover the entire E1E2 sequence of a HCV genotype 1b 210 
isolate. The sequences and the layout of peptides spotted on the chip are presented in Supplementary File 211 
1. For peptide ELISA, plates were loaded with 2.5 µg/well of dissolved peptides (GenScript, USA) and 212 
incubated overnight at 4°C. After washing and blocking for 1 hour, serial dilutions of mAb A6 were 213 
added followed by incubation for 1 hour. Plates were washed and HRP-conjugated goat-anti-human IgG 214 
was added. After 1 hour of incubation, plates were washed, TMB substrate was added and the OD was 215 
measured as described previously. 216 
 217 
2.7. Generation and neutralization of HCVpp 218 
HCV pseudoparticles were produced as previously described (Hsu et al., 2003). Briefly, using 219 
calcium phosphate method (Promega), 293T cells were co-transfected with two constructs: 220 
pcDNA3.1/Hygro-E1E2 and pNL4-3.Luc.R–E– (envelope-deficient HIV-1 proviral genome with a 221 
luciferase reporter). Isolates used for HCVpp production included genotype 1a (H77), genotype 1b (UG-222 
P09-779, UG-P10-252 and UG-P12-763) and genotype 2a (JFH1) strains. Supernatant containing HCVpp 223 
was collected 72 hours post transfection, sterile filtered through 0.45 µm filter and stored at –80°C. For 224 
HCVpp neutralization, 1x104 Hep3B cells were seeded in 96-well tissue culture plate and incubated at 225 
37°C and 5% CO2. The following day, HCVpp were mixed with mAb A6 (100 µg/mL) or anti-E1 mAb 226 
IGH526 (10 µg/mL) or anti-E2 mAbs (MRCT10, 1:7, HC84.26, CBH-7 and HC-1AM; 10 µg/mL) or 227 
combinations. The mixture was incubated for 1 hour at 37°C before it was added to the Hep3B culture. 228 
After 72 hours, intracellular luciferase activity was measured to estimate HCVpp infection (Promega). 229 
 230 
2.8. HCVcc production and neutralization 231 
Cell culture-derived HCV (HCVcc) of isolates H77c/JFH1 (genotype 1a), J4/JFH1 (genotype 1b) and 232 
J6/JFH1 (Jc1; genotype 2a) was produced as described previously with some modifications (Wakita et al., 233 
2005). Briefly, XbaI linearized HCV plasmids were in vitro transcribed (Promega) and the RNA was used 234 
for transfection of Huh-7.5RFP-NLS-IPS cells using Lipofectamine 2000 reagent (Invitrogen). Culture 235 
supernatant was harvested, sterile filtered and stored at –80°C. For HCVcc neutralization, 1.3x104 Huh-236 
7.5RFP cells were seeded in a 96-well plate. The next day, mAb A6 (100 µg/mL) or MRCT10 (10 µg/mL) 237 
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was pre-incubated with 50-100 focus forming units (FFUs) of HCVcc at 37°C for 1 hour. The mixture 238 
was then added to Huh-7.5RFP cells and incubated for 4 hours followed by washing and incubation for 239 
another 48 hours. Infected cells were immunostained with mouse anti-NS5A mAb 9E10 (kindly provided 240 
by Dr. Charles Rice, Rockefeller University, USA) and Alexa 647 conjugated goat-anti-mouse IgG 241 
(Invitrogen). The number of FFUs were determined using the BD Pathway 435 High Content Bioimager 242 
(BD Biosciences). To test the suitability of mAb A6 for immunofluorescence imaging, H77c/JFH1 243 
infected cells were incubated overnight at RT with mAb A6 (1 µg/mL), after which Alexa 647-conjugated 244 
goat-anti-human IgG was added for visualization. As a positive control, the same cells were stained with 245 
the anti-NS5A mAb 9E10, in combination with Alexa 488-conjugated goat-anti-mouse IgG.  246 
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3. Results 249 
3.1. Amplification of E1E2 from Belgian isolates 250 
Following E1E2 amplification and agarose gel electrophoresis, bands of approximately 1.7kb, 251 
corresponding to full length E1E2 coding genes were cloned into mammalian expression vector and 252 
sequenced (data not shown). The names and accession numbers of previously published sequences are 253 
listed in Table 1. Multiple sequence alignment and phylogenetic analysis showed that our sequences 254 
correspond to 28 new viral isolates (Supplementary Fig. 1) and are of genotype 1b, except for one isolate 255 
that is classified as genotype 1a (Fig. 1).  256 
 257 
3.2. Human mAb A6 efficiently binds to recombinant E1E2 proteins 258 
Hybridoma cell lines were prepared from B lymphocytes of a chronic HCV carrier as described 259 
before (Depraetere et al., 2001). Screening of hybridoma culture supernatants identified a clone secreting 260 
an HCV E1-specific antibody, designated A6. To evaluate the binding affinity of this antibody to 261 
recombinant HCV envelope (E1E2), expression vectors encoding the HCV envelope proteins were used 262 
to transfect 293T cells and cell lysates were used in GNA binding ELISA. As shown in Fig. 2A and B, 263 
sigmoidal dose response curves were observed when cell lysate containing E1E2 of three genotype 1a 264 
(H77, UKN1A20.8 and UKN1A14.38), one genotype 1b (UKN1B12.16) and two genotype 2a 265 
(UKN2A1.2 and JFH1) isolates were used. Similar binding experiments were performed using cell lysates 266 
containing E1E2 of multiple isolates. These included previously published genotype 1b isolates (J4, 267 
UKN1B5.23, P5VD, P5VE and P5VF), the 28 Belgian isolates of genotype 1a and 1b mentioned above as 268 
well as isolates of genotype 2b (UKN2B2.8), genotype 3a (S52), genotype 4 (UKN4.11.1), genotype 5 269 
(UKN5.14.4) and genotype 6 (UKN6.5.8). Overall, GNA ELISA binding data showed that mAb A6 270 
antibody efficiently reacts with full length E1E2 envelope glycoproteins of genotypes 1a, 1b and 2a, but 271 
not with E1E2 of genotypes 2b, 3a, 4, 5 and 6 (Fig. 2C). 272 
 273 
3.3. Antibody A6 recognizes the region AA 230-239 of E1  274 
To identify the region critical for mAb A6 binding, we used a custom-made peptide microarray 275 
spanning the complete E1E2 sequence. Upon incubation of array chip with mAb A6, reactive spots were 276 
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observed with peptides spanning amino acids 225-243 of the HCV E1 protein, while no reactivity was 277 
seen in any other regions within E1 or E2 (Fig. 3A). The sequences of peptides spanning the full length 278 
E1E2 are presented in Supplementary File 1 and peptides with positive reactivity to A6 are highlighted 279 
with grey background. To confirm this result, 11 individual peptides spanning the region 222-246 were 280 
produced for use in traditional peptide ELISA. As shown in Figure 3B, antibody A6 reacted with peptides 281 
spanning the region AA 225-244, thereby confirming the results obtained with the PEPperPRINT 282 
microarray assay. Since the peptides used in these assays are not glycosylated, we can assume that the 283 
glycosylation of the HCV envelope protein in this region is not essential for mAb binding. To test this 284 
hypothesis, we performed peptide-based competition assay. In this assay, ELISA plates pre-coated with 285 
recombinant E1E2 protein of H77 isolate were loaded with serial dilutions of individual peptides together 286 
with a fixed concentration of mAb A6. This showed the ability of the peptides spanning AA 225-244 to 287 
efficiently compete with recombinant E1E2 for binding to mAb A6, which confirms that A6-binding is 288 
glycosylation independent (Fig. 3C). The glycosylation-independent reactivity of mAb A6 was confirmed 289 
using Western blotting analysis of PNGase F-treated, Endo H-treated and non-treated E1E2 cell lysate, 290 
where mAb A6 binds to both glycosylated and deglycosylated E1 (Fig. 4). Overall, our data indicates that 291 
the minimal epitope of antibody A6 encompasses AA 230-239 of HCV E1. 292 
 293 
3.4. The epitope identified by mAb A6 has a linear conformation 294 
In order to assess whether the A6 epitope has a linear or conformational structure, we performed a 295 
denaturation binding assay. Binding of A6 to native and denatured E1E2-containing cell lysate was 296 
assessed and compared to the binding activity of antibodies A4 and 1:7, targeting respectively a linear E1-297 
epitope and a conformational epitope within E2. While denaturation of H77 E1E2 only minimally 298 
affected binding of antibodies A4 and A6, that of mAb 1:7 was completely abolished (Fig. 5A). Likewise, 299 
denaturation of JFH1 E1E2 did not negatively impact A6 binding, while the binding of mAb 1:7 was 300 
completely lost (Fig. 5B). The absence of A4 binding to both native and denatured JFH1 E1E2 protein is 301 
explained by its non-reactivity towards genotype 2 isolates. Altogether, these data show that the epitope 302 
targeted by mAb A6 has a linear, denaturation-resistant structure. 303 
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To investigate potential conservation of the A6 epitope among different HCV genotypes, amino acid 304 
sequences of E1 for isolates used in the binding assay were aligned using BioEdit and CLC main 305 
workbench. As seen from the sequence alignment and the percentage of conservation, certain amino acids 306 
in region 230-239, which is critical for mAb A6 binding, are highly conserved especially among 307 
genotypes 1a and 1b (Fig. 6). Amino acids cysteine and tryptophan at sites 238 and 239 respectively are 308 
conserved in all 7 genotypes. The residues 234N and 236S are also conserved, except in case of genotype 309 
2b where they are replaced by glycine and leucine, respectively. Likewise for 230V, which is only 310 
different for genotype 2. Other positions such as 231, 232 and 237 show high conservation among 311 
genotypes 1a, 1b and 2a compared to genotypes 2b, 3a, 4, 5 and 6. 312 
 313 
3.5. Antibody A6 does not neutralize HCVpp and HCVcc 314 
Since mAb A6 efficiently binds to E1E2, we next wanted to investigate its neutralizing activity. 315 
Therefore, HCVpp from genotypes 1a (H77 isolate), 1b (UG-P09-779, UG-P10-252 and UG-P12-763) 316 
and 2a (JFH1 isolate) were produced and used in neutralization assays. Incubation of mAb A6 with 317 
HCVpp before addition to Hep3B cell cultures did not protect the target cells from infection, even at high 318 
mAb concentration (100 µg/mL) (Fig. 7A-E). In parallel, 10 µg/mL of the AP33-derived humanized mAb 319 
MRCT10 was included as positive control and completely prevented HCVpp infection of all tested 320 
genotypes. These results indicate that mAb A6 does not exhibit any neutralizing activity in the HCVpp 321 
system, despite its capacity to efficiently bind the viral envelope.  322 
Subsequently we also tested the neutralizing capacity of mAb A6 in the context of the HCV cell 323 
culture (HCVcc) system. Three universally used chimeric viruses H77c/JFH1, J4/JFH1 and Jc1 (J6/JFH1), 324 
incorporating the envelope proteins of isolates H77c (genotype 1a), J4 (genotype 1b) and J6 (genotype 2a) 325 
respectively, were pre-incubated with A6 or MRCT10, after which the mixture was transferred to Huh7.5 326 
hepatoma cells. Enumeration of the number of infected foci 2 days later showed that mAb A6 was unable 327 
to protect Huh7.5 cells from HCVcc challenge, while MRCT10 did (Fig. 7F-H). Altogether, our HCVpp 328 
and HCVcc data indicate that mAb A6 has no neutralizing activity. However, staining of H77c/JFH1 329 
infected Huh7.5RFP cells with mAb A6 enabled the visualization of infected cells which indicates the 330 
applicability of mAb A6 for use in immunofluorescence (Fig. 8). 331 
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 332 
3.6. mAb A6 does not interfere with neutralizing antibodies 333 
A broadly neutralizing determinant encompassing residues 412-423 of E2 has previously been shown 334 
to be susceptible to antibody interference (Kachko et al., 2015; Zhang et al., 2009), although this is 335 
controversial (Tarr et al., 2012). In this regard, we examined if antibody A6 could interfere with the 336 
binding and/or protective activity of other known neutralizing antibodies. Murine mAb AP33 is one of the 337 
most extensively studied antibodies that target a linear epitope within HCV E2 protein and exhibits broad 338 
neutralizing activity both in vitro and in vivo (Desombere et al., 2016; Owsianka et al., 2005). In a first 339 
setup, full length E1E2 protein of isolate H77 was incubated with serial dilutions of mAb A6 before 340 
addition of biotinylated AP33. Subsequent addition of HRP-conjugated streptavidin enabled us to assess 341 
the amount of biotinylated antibody that still was able to bind to the envelope proteins. As can be seen in 342 
Figure 9A, mAb A6 did not interfere with the binding the biotinylated AP33 whereas the humanized 343 
version of AP33, mAb MRCT10, inhibited the subsequent binding of biotinylated AP33 in a dose-344 
dependent manner. To confirm the non-interfering nature of A6, HCVpp neutralization was performed 345 
using H77 and JFH1 isolates in the presence of mAbs A6, MRCT10, IGH526, 1:7, HC84.26, CBH-7 and 346 
HC-1AM alone or in combination. Measurement of luciferase activity showed that MRCT10 efficiently 347 
inhibited HCVpp infection of both genotypes, while the co-incubation of mAb A6 did not interfere with 348 
this activity (Fig. 9B and C). Similarly, mAb A6 did not negatively impact the neutralizing activity of 349 
mAbs IGH526, 1:7, HC84.26, CBH-7 and HC-1AM. These mAbs have been previously shown to have 350 
cross-neutralizing activity against HCVpp and HCVcc (Johansson et al., 2007; Keck et al., 2004a; Keck 351 
et al., 2012; Wang et al., 2011b). Based on our ELISA and HCVpp competition experiments we can 352 
conclude that our anti-E1 mAb A6 does not interfere with the neutralizing activity of known anti-E2 353 
mAbs. 354 
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4. Discussion 357 
In the current study, we describe the development and characterization of a novel human monoclonal 358 
antibody (designated A6) isolated by hybridoma technology from the PBMCs of a patient chronically 359 
infected with HCV genotype 1b. Epitope mapping identified the region encompassing AA 230-239, 360 
located at the N-terminal region of E1, as the critical region for binding. Previously, two other regions 361 
within E1 have been described that elicit E1-specific antibodies. The first is the N-terminal region 362 
recognized by human mAb H-111 (AA 192-202) (Keck et al., 2004b) and murine mAb A4 (AA 197-207) 363 
(Dubuisson et al., 1994), which lies upstream of the epitope recognized by A6. The second antigenic 364 
region within E1 encompasses AA 313-327, which is located at the C-terminal region and is recognized 365 
by cross-neutralizing mAbs such as IGH505 and IGH526 (Meunier et al., 2008). mAb H-111 was isolated 366 
from a patient chronically infected with HCV of genotype 1b and showed high binding activity to E1 367 
protein from genotypes 1a, 1b, 2b. It bound only moderately to HCV of genotype 3a, and no binding was 368 
observed to genotype 2a and 4a. It also exhibited some neutralizing activity towards HCV-like particles 369 
and HCVpp, but complete prevention of infection was not achieved (Dreux et al., 2006; Keck et al., 370 
2004b). To evaluate the binding activity of mAb A6 , we used full length E1E2 protein that was expressed 371 
in mammalian cells. New isolates from Belgian patients, genotyped as 1a and 1b, have been used together 372 
with well-known isolates covering genotypes 1 to 6. Active binding of mAb A6 to all isolates of 373 
genotypes 1a (4 isolates), 1b (33 isolates) and 2a (2 isolates) was observed, while no binding activity was 374 
seen with the other genotypes (2b, 3a, 4, 5 and 6; one isolate for each genotype). This resembles the mAb 375 
H-111 in binding to genotypes 1a and 1b (Keck et al., 2004b). The major difference between the mAb H-376 
111 study and A6 is that we used full length E1E2 proteins instead of E1. Altogether these data confirm 377 
that the activity of antibodies raised against the N-terminal region of E1 is genotype dependent. 378 
Although the sequence of the HCV envelope exhibits great variability across genotypes, conserved 379 
glycosylation sites in E1, including the N-terminal region, and E2 have been identified and shown to play 380 
a role in evasion from host immunity (Dubuisson et al., 1994; Goffard and Dubuisson, 2003; Helle et al., 381 
2011; Helle et al., 2010). Since the recombinant E1E2 proteins used in our binding ELISA were 382 
expressed in mammalian cells, their proper glycosylation and post-translational modification may be 383 
expected. In contrast, synthetic peptides used in epitope mapping are non-glycosylated. For this reason, 384 
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we have also examined the effect of these peptides in a competition assay together with recombinant 385 
E1E2 protein. The strong inhibition of binding of mAb A6 to E1E2 glycoprotein upon addition of 386 
synthetic peptides indicates that this binding is not relying on the glycosylation of E1. This was 387 
corroborated by Western blot analysis, which showed positive reactivity of mAb A6 to both glycosylated 388 
and (PNGase/Endo H) deglycosylated E1 (Dubuisson et al., 2000). In addition, the envelope of HCV 389 
contains multiple intramolecular disulfide bonds which are essential for proper folding and stabilizing 390 
(Krey et al., 2010). Incubation of recombinant envelope glycoprotein with SDS and DTT at high 391 
temperature destroys these disulfide bonds and disrupts the secondary structure of the protein. This 392 
approach has been used to differentiate between antibodies targeting linear versus conformation-393 
dependent epitopes (Keck et al., 2012; Tarr et al., 2006). mAb A6 efficiently recognized the envelope of 394 
both native and denatured E1E2 proteins and a similar result was obtained for mAb A4 that previously 395 
shown to target a linear epitope within E1. In parallel, mAb 1:7 that targets a conformational epitope 396 
within E2 completely lost its binding upon denaturation of the envelope proteins, confirming previous 397 
findings (Allander et al., 2000; Johansson et al., 2007). Altogether, our results indicate that the mAb A6 398 
targets a linear epitope within the N-terminus of the E1 protein. Multiple sequence alignment of the E1 399 
protein using all isolates used in the current study in addition to previously published sequences revealed 400 
the highly conserved nature of residues 230, 234, 236, 238 and 239 within the A6 epitope among different 401 
genotypes. However, the change of polar amino acids at residues 234 and 236 to more hydrophobic ones 402 
may be the underlying cause of the absence of reactivity of mAb A6 towards genotype 2b isolates. On the 403 
other hand, residues at sites 231, 232 and 237 are highly conserved among isolates of genotypes 1a, 1b 404 
and 2a compared to the high variation observed in other genotypes like 2b, 3a, 4, 5 and 6. Altogether this 405 
may explain the efficient and specific binding of mAb A6 with the E1 envelope protein of isolates of 406 
genotypes 1a, 1b and 2a. Similar sequence conservation has been shown upon alignment of the C-407 
terminal region, a region that is identified by cross-neutralizing antibodies (Bukh et al., 1993; Meunier et 408 
al., 2008).  409 
Using the HCVpp system, mAb A6 could not inhibit the entry of pseudoparticles of genotypes 1a, 1b 410 
and 2a, while complete protection was achieved by mAb MRCT10 - the humanized version of the cross-411 
neutralizing mAb AP33 (Owsianka et al., 2001; Pantua et al., 2013). Previous studies showed low 412 
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neutralizing activity of the human mAb H-111 while the neutralizing potential of mAb A4 has not been 413 
reported (Dubuisson et al., 1994; Keck et al., 2004b). Nevertheless, the non-neutralizing function of 414 
antibodies raised against the N- terminal region cannot be generalized to all E1-specific mAbs since the 415 
two mAbs, IGH505 and IGH526, that target the region AA 313-327 showed cross-neutralizing capacity 416 
when tested in the HCVpp and HCVcc systems (Meunier et al., 2008). Since HCVpp are produced in 417 
293T cells, a non-hepatic cell line, its lipoprotein profile may differ from the that of genuine HCV virions 418 
produced in infected patients and from HCVcc produced in hepatic cell lines. In order to confirm the 419 
results obtained with the HCVpp system, we performed similar neutralization experiments in the HCVcc 420 
system. Despite the use of high antibody concentration mAb A6 was also unable to protect Huh7.5 cells 421 
from infection.  422 
Some studies have reported that antibodies raised against certain epitopes within E2 interfere with the 423 
neutralizing activity of other antibodies. For example, antibodies targeting epitope II (AA 434-446) 424 
within E2 protein have been shown to interfere with the neutralizing activity of other mAbs targeting 425 
epitope I (AA 412-424) (Kachko et al., 2015; Zhang et al., 2007; Zhang et al., 2009) although others 426 
contradicted this finding (Tarr et al., 2012). No data is available about the potential interfering activity of 427 
E1 antibodies. We therefore examined whether A6 interfered with the activity of anti-E1 antibody 428 
IGH526 and anti-E2 mAbs MRCT10 (epitope I-specific), 1:7 (AA 523-535; domain B-specific), HC84.26 429 
(epitope II-specific), CBH-7 (domain C-specific) and HC-1AM (domain B-specific) and found out that it 430 
did not. A recent study reported that antibodies against non-neutralizing epitopes within E1 and E2 can be 431 
involved in antibody-dependent cytotoxic responses by natural killer cells (Long et al., 2017). This new 432 
finding suggests that non-neutralizing, non-interfering antibodies like A6 may still play a role in the 433 
immune control of HCV. More in depth exploration of this mechanism is warranted.  434 
In conclusion, we report that the region spanning AA 230-239 at the N-terminal region of E1 is 435 
immunogenic and can elicit non-neutralizing Abs during a chronic HCV infection cross-reactive to 436 
genotypes 1a, 1b and 2a. mAb A6 can be considered as one more tool that could help to elucidate the 437 
structure of the viral envelope, an important step in the development of an effective prophylactic HCV 438 
vaccine. 439 
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Figure legends 641 
Fig. 1. Phylogenetic tree for new E1E2 isolates. Following isolation and sequencing of full length E1E2 642 
from Belgian patients infected with HCV, sequences were multiple aligned together with previously 643 
published sequences retrieved from the HCV database. Neighbor joining phylogenetic tree was 644 
constructed using CLC main workbench based on the whole E1E2 amino acid sequence. Analysis shows 645 
that all Belgian isolates belong to genotype 1b, except for one isolate genotyped as 1a. The 28 Belgian 646 
genotype 1a and 1b isolates are highlighted in red. Bootstrap values are indicated. 647 
Fig. 2. Binding of mAb A6 to recombinant E1E2. Constructs encoding the full length E1E2 of HCV 648 
genotypes 1-6 were used for expression in 293T cells. GNA-coated ELISA plates were loaded with cell 649 
lysate containing E1E2. (A and B) Binding of serially diluted mAb A6 was assessed using ELISA plates 650 
coated with E1E2 of three genotype 1a isolates (H77, UKN1A20.8, UKN1A14.38), one genotype 1b 651 
(UKN1B12.16) and two genotype 2a isolates (UKN2A1.2 and JFH1). (C) mAb A6 binding to the 652 
envelope proteins of multiple other isolates of different genotypes was evaluated at fixed antibody 653 
concentration (10 µg/mL). Lysate of non-transfected 293T cells was included as a negative control. All 654 
conditions were performed in duplicate and error bars represent the standard deviation.  655 
Fig. 3. Epitope mapping of mAb A6. (A) To identify the epitope within E1E2 recognized by mAb A6, a 656 
custom-made chip (PEPperPRINT) with printed overlapping peptides spanning the complete E1E2-657 
sequence was used. After incubation with mAb A6 and an Alexa647-conjugated goat anti-human IgG, 658 
spots corresponding to 5 different E1-specific peptides appeared (highlighted with black square). The 659 
reactive peptides were AA 225-239, AA 226-240, AA 227-241, AA 228-242 and AA 229-243. The 660 
positive spots in the outer rim of the chip are controls that are used for localization purposes only. (B) 661 
Standard peptide ELISA was performed using synthetic peptides spanning the region AA 222-246 (25 662 
µg/mL). mAb A6 was used at 10 µg/mL and binding activity is shown by OD values measured at 450nm. 663 
(C) A peptide competition assay was performed on ELISA plates coated with recombinant E1E2 (H77 664 
isolate), using a fixed concentration of mAb A6 (20 µg/mL) in the presence of serial dilutions of the 665 
indicated synthetic peptides. Binding of mAb A6 is denoted as % of maximal binding in the absence of 666 
synthetic peptide. The amino acid sequence of the peptides covering the region AA 222-246 used in (A-C) 667 
is indicated. 668 
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Fig. 4. Reactivity of mAb A6 to glycosylated and deglycosylated E1E2 protein. Lysate of 293T cells 669 
expressing H77 E1E2 was treated with PNGase F or Endo H. Following 12% SDS-PAGE, proteins were 670 
transferred to a nitrocellulose membrane and revealed using mAb A6 as primary antibody. Positive bands 671 
were visible at a molecular weight around 20-22 kDa in case of PNGase F and Endo H-treated cell lysate 672 
(lane 3 and 4), which correspond to deglycosylated E1, while the untreated lysate showed reactive bands 673 
at around 25-32 kDa (lane 2). The position and molecular weights of protein standard are presented in 674 
kDa (lane M). The deglycosylated E1 protein is indicated by an asterisk. 675 
Fig. 5. Antibody A6 targets a linear epitope. To investigate if the region targeted by mAb A6 is 676 
conformation sensitive or not, cell lysate containing E1E2 of isolate H77 (genotype 1a) (A) or JFH1 677 
(genotype 2a) (B) was denatured by incubation with SDS and DTT at 56°C. Native and denatured cell 678 
lysate were coated on ELISA plates and binding of mAb A6 (5 μg/mL) was assessed. In parallel, murine 679 
mAb A4 and human mAb 1:7 were included as controls for linear and conformational epitopes 680 
respectively. All conditions were performed in duplicate and results are shown as the mean +/- standard 681 
deviation. 682 
Fig. 6. Multiple alignment of the region corresponding to AA 192-250 and AA 310-330 of HCV E1. 683 
The E1 sequence of all HCV isolates used in the current study was retrieved from GenBank and the HCV 684 
database and multiple aligned using BioEdit software. The epitopes targeted by antibodies H-111, A4, A6, 685 
IGH505 and IGH526 are indicated using colored squares. The dots indicate conservation of the residue 686 
relative to the reference prototype H77 (genotype 1a). The lower part of the alignment shows the 687 
consensus sequence and the percentage of overall conservation calculated using CLC Main Workbench. 688 
Fig. 7. HCVpp and HCVcc neutralization. In order to verify the neutralizing capacity of mAb A6, 689 
HCVpp expressing E1E2 of H77 (genotype 1a) (A), UG-P09-779 (genotype 1b) (B), UG-P10-252 690 
(genotype 1b) (C), UG-P12-763 (genotype 1b) (D) and JFH1 (genotype 2a) (E) were incubated for 1 hour 691 
at 37°C with mAb A6 (100 µg/mL) or with mAb MRCT10 (10 µg/mL) before addition to Hep3B cells. 692 
After 72 hours, HCVpp infection was assessed by quantifying the luciferase reporter gene expression and 693 
the results were normalized to untreated controls (Ctrl). Chimeric HCVcc of genotypes 1a/2a (F), 1b/2a 694 
(G) and 2a/2a (H) were pre-incubated with mAb A6 at a concentration of 100 µg/mL or with 10 µg/mL of 695 
mAb MRCT10 for 1 hour at 37 °C before exposure to Huh7.5RFP cells. The number of HCV-infected 696 
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foci was counted using NS5A-specific antibody staining. The infection was normalized to that in cultures 697 
that were exposed to virus only (Ctrl). All conditions were performed in triplicate and results are shown 698 
as the mean +/- standard deviation. 699 
Fig. 8. mAb A6-based visualization of infected Huh7.5RFP cells using immunofluorescence. 700 
H77c/JFH1 infected Huh7.5RFP cells (upper panel) and non-infected cells (-ve; lower panel) were 701 
incubated overnight with mAb A6 (middle column), after which Alexa 647-conjugated goat-anti-human 702 
IgG was added. As a positive control, the same cells were stained with anti-NS5A mAb 9E10 in 703 
combination with Alexa 488 conjugated goat-anti-mouse IgG (right column). DAPI was used as 704 
counterstain (left column). 705 
Fig. 9. mAb A6 does not interfere with neutralizing antibodies. (A) Competition ELISA was 706 
performed using biotinylated AP33 and E1E2 of isolate H77 as a coating antigen. Serial dilutions of mAb 707 
A6 were used starting at 30 µg/ml and the binding of biotinylated AP33 was measured using HRP-708 
conjugated streptavidin. As a positive control for inhibition, serial dilutions of MRCT10 were used in 709 
parallel. To investigate the interference with the neutralizing potential of anti-E2 antibodies, HCVpp from 710 
genotype 1a (H77) (B) and 2a (JFH1) (C) were used. Co-incubation of mAb A6 (100 µg/mL) and one of 711 
anti-E1 or anti-E2 mAbs (IGH526, MRCT10, 1:7, HC84.26, CBH-7, HC-1AM; 10 µg/mL) and HCVpp 712 
was done one hour before addition to Hep3B cells. The luciferase activity was determined and the 713 
percentage of neutralization was calculated relative to infection in the absence of antibody (Ctrl). All 714 
conditions were performed in duplicate for ELISA and 5 replicates for HCVpp inhibition. Results are 715 
shown as the mean +/- standard deviation. 716 
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Table 1: Names, genotypes and accession numbers for the E1E2 isolates used in ELISA. 
 
Isolate ID Genotype Accession number 
H77 1a AF011751 
UKN1A20.8 1a EU155192 
UKN1A14.38 1a AY734971 
J4 1b AF054250 
UKN1B5.23 1b AY734976 
UKN1B12.16 1b AY734974 
P5VD 1b (Fafi-Kremer et al., 2010) 
P5VE 1b (Fafi-Kremer et al., 2010) 
P5VF 1b (Fafi-Kremer et al., 2010) 
UG-P08-503 1b (Desombere et al., 2016) 
UG-P09-779 1b (Desombere et al., 2016) 
UG-P10-252 1b (Desombere et al., 2016) 
UG-P12-763 1b (Desombere et al., 2016) 
JFH1 2a AB047639 
UKN2A1.2 2a AY734977 
UKN2B2.8 2b AY734983 
S52 3a GU814263 
UKN4.11.1 4 AY734986 
UKN5.14.4 5 AY785283 
UKN6.5.8 6 EF427671 
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